Viridian Therapeutics Inc (NASDAQ: VRDN) kicked off on Tuesday, down -3.86% from the previous trading day, before settling in for the closing price of $15.29. Over the past 52 weeks, VRDN has traded in a range of $10.93-$24.18.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -12.71%. While this was happening, its average annual earnings per share was recorded 28.58%. With a float of $55.83 million, this company’s outstanding shares have now reached $63.89 million.
The extent of productivity of a business whose workforce counts for 96 workers is very important to gauge.
Viridian Therapeutics Inc (VRDN) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Viridian Therapeutics Inc is 12.61%, while institutional ownership is 98.30%. The most recent insider transaction that took place on Jan 22 ’24, was worth 9,999,990. In this transaction Director of this company bought 476,190 shares at a rate of $21.00, taking the stock ownership to the 1,839,954 shares.
Viridian Therapeutics Inc (VRDN) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 28.58% per share during the next fiscal year.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
Take a look at Viridian Therapeutics Inc’s (VRDN) current performance indicators. Last quarter, stock had a quick ratio of 23.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3238.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.25, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -4.06 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
The latest stats from [Viridian Therapeutics Inc, VRDN] show that its last 5-days average volume of 0.64 million was inferior to 0.97 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 30.28%. Additionally, its Average True Range was 1.01.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 43.02%, which indicates a significant increase from 17.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.52% in the past 14 days, which was lower than the 57.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.87, while its 200-day Moving Average is $16.37. Now, the first resistance to watch is $15.18. This is followed by the second major resistance level at $15.67. The third major resistance level sits at $16.00. If the price goes on to break the first support level at $14.36, it is likely to go to the next support level at $14.03. The third support level lies at $13.54 if the price breaches the second support level.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
The company with the Market Capitalisation of 939.18 million has total of 63,822K Shares Outstanding. Its annual sales at the moment are 310 K in contrast with the sum of -237,730 K annual income. Company’s last quarter sales were recorded 70 K and last quarter income was -64,990 K.
